What is X4 Pharmaceuticals Financial Strength?
X4 Pharmaceuticals has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
X4 Pharmaceuticals did not have earnings to cover the interest expense.
As of today, X4 Pharmaceuticals's Altman Z-Score is 0.00.
Competitive Comparison of X4 Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, X4 Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's Financial Strength falls into.
X4 Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
X4 Pharmaceuticals's Interest Expense for the
months ended in Mar. 2024 was $-1.87 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-37.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $57.14 Mil.
X4 Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
| X4 Pharmaceuticals did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
X4 Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
X4 Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.
Executives
| Paula Ragan |
director, officer: President and CEO |
C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139 |
| Mark Baldry |
officer: Chief Commercial Officer |
C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
| Arthur Taveras |
officer: Chief Scientific Officer |
C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134 |
| Mary Dibiase |
officer: Chief Operating Officer |
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134 |
| Adam S. Mostafa |
officer: See Remarks |
C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134 |
| Keith Woods |
director |
C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134 |
| Michael S Wyzga |
director |
RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
| Christophe Arbet-engels |
officer: Chief Medical Officer |
C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104 |
| Murray Stewart |
director |
C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
| Craecker Francoise De |
director |
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134 |
| Derek M Meisner |
officer: General Counsel |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
| Diego Cadavid |
officer: Chief Medical Officer |
C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Alison Frances Lawton |
director |
39 ROBINSON ROAD, LEXINGTON MA 02420 |
| Renato Skerlj |
officer: Chief Scientific Officer |
C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139 |
| William Aliski |
director |
C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
X4 Pharmaceuticals (X4 Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XFOR has been successfully added to your